| Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype L Gerratana, D Basile, G Buono, S De Placido, M Giuliano, S Minichillo, ... Cancer treatment reviews 68, 102-110, 2018 | 241 | 2018 |
| Hormone receptor/human epidermal growth factor receptor 2-positive breast cancer: where we are now and where we are going F Schettini, G Buono, C Cardalesi, I Desideri, S De Placido, L Del Mastro Cancer treatment reviews 46, 20-26, 2016 | 121 | 2016 |
| Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? G Buono, L Gerratana, M Bulfoni, N Provinciali, D Basile, M Giuliano, ... Cancer Treatment Reviews 73, 73-83, 2019 | 104 | 2019 |
| Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial S De Placido, C Gallo, M De Laurentiis, G Bisagni, G Arpino, MG Sarobba, ... The Lancet Oncology 19 (4), 474-485, 2018 | 83 | 2018 |
| Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy G Arpino, C De Angelis, G Buono, A Colao, M Giuliano, S Malgieri, ... Breast cancer research and treatment 154, 127-132, 2015 | 54 | 2015 |
| Prostate cancer peripheral blood NK cells show enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 production and secrete monocyte-recruiting and polarizing factors M Gallazzi, D Baci, L Mortara, A Bosi, G Buono, A Naselli, A Guarneri, ... Frontiers in immunology 11, 586126, 2021 | 52 | 2021 |
| Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study G Buono, A Crispo, M Giuliano, C De Angelis, F Schettini, V Forestieri, ... Breast cancer research and treatment 182, 401-409, 2020 | 43 | 2020 |
| Innate immunity effector cells as inflammatory drivers of cardiac fibrosis D Baci, A Bosi, L Parisi, G Buono, L Mortara, G Ambrosio, A Bruno International journal of molecular sciences 21 (19), 7165, 2020 | 38 | 2020 |
| T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study B Conte, A Fabi, F Poggio, E Blondeaux, C Dellepiane, A D’Alonzo, ... Clinical Breast Cancer 20 (2), e181-e187, 2020 | 37 | 2020 |
| Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results S De Placido, M Giuliano, F Schettini, C Von Arx, G Buono, F Riccardi, ... The Breast 38, 86-91, 2018 | 32 | 2018 |
| PI3K/mTOR inhibitors in the treatment of luminal breast cancer. Why, when and to whom F Schettini, G Buono, MV Trivedi, S De Placido, G Arpino, M Giuliano Breast Care 12 (5), 290-294, 2017 | 27 | 2017 |
| Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study G Buono, A Crispo, M Giuliano, C De Angelis, F Schettini, V Forestieri, ... Oncotarget 8 (70), 115709, 2017 | 22 | 2017 |
| Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists M Ottaviano, M Curvietto, P Rescigno, M Tortora, G Palmieri, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 20 | 2020 |
| Burning fog: cognitive impairment in burning mouth syndrome F Canfora, E Calabria, R Cuocolo, L Ugga, G Buono, G Marenzi, ... Frontiers in Aging Neuroscience 13, 727417, 2021 | 19 | 2021 |
| Pretreatment serum concentration of vitamin D and breast cancer characteristics: a prospective observational mediterranean study G Buono, M Giuliano, C De Angelis, R Lauria, V Forestieri, M Pensabene, ... Clinical Breast Cancer 17 (7), 559-563, 2017 | 17 | 2017 |
| Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women A Crispo, M Montella, G Buono, M Grimaldi, M D’Aiuto, I Capasso, ... Current research in translational medicine 64 (1), 15-20, 2016 | 17 | 2016 |
| Breast cancer adjuvant radiotherapy in BRCA1/2, TP53, ATM genes mutations: Are there solved issues? G Lazzari, G Buono, B Zannino, G Silvano Breast Cancer: Targets and Therapy, 299-310, 2021 | 15 | 2021 |
| T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study F Schettini, B Conte, G Buono, P De Placido, S Parola, G Griguolo, A Fabi, ... ESMO open 6 (2), 100099, 2021 | 14 | 2021 |
| Prevalence of sarcopenia in women with breast cancer D Morlino, M Marra, I Cioffi, L Santarpia, P De Placido, M Giuliano, ... Nutrients 14 (9), 1839, 2022 | 12 | 2022 |
| Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting S Del Prete, L Montella, G Arpino, G Buono, C Buonerba, P Dolce, ... Oncotarget 11 (22), 2083, 2020 | 9 | 2020 |
Sabino De PlacidoProfessore Ordinario di Oncologia MedicaVerified email at unina.it
